Complera (Rilpivirine/Tenofovir/FTC)

Complera (rilpivirine/tenofovir/emtricitabine) is a multi-class combination drug used to treat HIV/AIDS. It is approved by the U.S. FDA for the treatment of HIV infection in adults with an HIV viral load less than or equal to 100,000 copies/mL. It is listed in the HHS HIV treatment guidelines as an alternative regimen for people starting HIV treatment for the first time.

Adult single dose:Take one tablet once daily. Each tablet contains 200 mg of emtricitabine, 25 mg of rilpivirine, and 300 mg of tenofovir disoproxil fumarate.

Restrictions:

Take with food.

Complera should not be taken in combination with other anti-HIV medicines.

The Body is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.